Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)

Active
Yes
Status
Posted
Published Date
February 16th, 2024
Close Date
October 21st, 2024
Award Ceiling
$500,000.00
Opportunity No.
RFA-NS-24-032

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "Development and Validation of Human Cellular Models for Alzheimer's Disease-Related Dementias (ADRD) (R01 - Clinical Trial Not Allowed)". This grant aims to support the development and validation of novel human cellular models that are clinically and/or pathophysiologically relevant to ADRD. These cellular models should capture the various pathologies and multiple cell types observed in ADRDs. The validation process should include internal, face, construct, and predictive validation to the extent possible. The goal of these models is to aid in therapy development and enhance our understanding of human disease mechanisms and predisposition to developing neurodegenerative dementias. The models should be novel, complex, and address existing gaps in currently available models. Multidisciplinary teams are highly encouraged, and leveraging existing NIH cell repository resources is also encouraged. The grant has a funding ceiling of $500,000 and does not require cost sharing or matching. The deadline for applications is October 21, 2024. For more information and to apply, visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-032.html. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Description

This NOFO would support development and validation of novel clinically- and/or pathophysiologically-relevant human cellular models of ADRD. The cellular model systems would be expected to capture the multi-faceted pathologies and multiple cell types observed in ADRDs. Validation includes internal, face, construct, and predictive (to the extent possible) validation. These models can be developed/validated with the goal of supporting therapy development or better understanding of human disease mechanisms and mechanisms that uncover predisposition to developing neurodegenerative dementias. Human cellular models need to be novel, complex, and address a gap in the currently available models. Multidisciplinary teams will be highly encouraged. Leveraging the use of and depositing new cells into existing NIH cell repository resources will also be encouraged.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Multi-Scale Models Bridging Levels of Analysis in Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R01 Clinical Trial Not Allowed)". This grant aims to fund the establishment of multi-scale computational models that can simulate the dynamic changes associated with aging, Alzheimer's disease, and Alzheimer's disease-related dementias (AD/ADRD). The models should utilize various computational approaches such as mathematical and computational modeling, image analysis, artificial intelligence, and machine learning. The goal is to gain a better understanding of the aging processes and AD/ADRD at the molecular, cellular, network, cognitive, and behavioral levels. The grant does not require cost sharing or matching. The maximum award ceiling is $500,000. Other eligible applicants, in addition to academic institutions, include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The closing date for applications is June 13, 2024. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-016.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-016.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD (R61/R33 Clinical Trial Not allowed)". This grant aims to support innovative strategies that target and manipulate brain cell subtypes affected by aging, Alzheimer's Disease (AD), and AD-Related Dementias (ADRDs). The goal is to develop and utilize sophisticated tools to precisely target disease-relevant cell subtypes in aged and degenerating mammalian brains, and to monitor and manipulate these cells in vivo to address mechanistic hypotheses related to brain aging and AD/ADRD in animal models. The grant provides up to 2 years of support for pilot activities (R61 phase) and up to 3 years of support for implementation activities including hypothesis testing (R33 phase). Eligible applicants include various institutions and organizations. The deadline for applications is October 7, 2024. For more information, visit the [grant opportunity website](http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-25-024.html).
Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed)". This grant aims to support studies that investigate the mechanisms by which COVID-19 interacts with and/or modulates AD/ADRD-relevant phenotypes. The studies can be conducted using animal, cell culture, and/or human tissue models. The proposed models or experimental readouts should incorporate AD/ADRD risk factors, pathologies, or relevant comorbidities. The grant provides funding for mechanistic studies that address various aspects, including the impact of COVID-19 on CNS pathology and cognitive outcomes in the presence of AD/ADRD pathology, the acceleration of AD/ADRD pathology and cognitive deficits by COVID-19 in prodromal models, and the predisposition of COVID-19 for AD/ADRD and its interaction with comorbid conditions and risk factors. The grant does not require cost sharing or matching and is open to various eligible applicants. The deadline for application submission is October 4, 2024. For more information and to apply, visit the following link: [Neuropathological Interactions Between COVID-19 and ADRD Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-24-203.html).
Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Mechanistic Investigations into ADRD Multiple Etiology Dementias (R01 - Clinical Trial Not Allowed)". This grant is in the category of Health and falls under the funding instrument type of Grant. The grant does not require cost sharing or matching. The opportunity is discretionary and falls under CFDA number 93.866. The purpose of this grant is to support investigations into the cellular and molecular mechanisms of how and why multi-proteinopathy interactions drive worsening neurodegenerative processes and phenotypic outcomes in dementias with multiple etiologies. The grant aims to identify the mechanisms of co-pathology cellular and molecular interactions across brain regions and time, as well as determine the events that lead to worse phenotypic outcomes. The investigations should focus on a minimum of two relevant co-pathologies, such as tau, alpha-synuclein, TDP-43, TMEM106B, and vascular, with optional risk factors and co-morbidities. The grant is open to eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Organizations) and non-U.S. components of U.S. Organizations are not eligible to apply. The grant has an award ceiling of $500,000. The closing date for applications is October 4, 2024, and the archive date is November 9, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html](http://grants.nih.gov/grants/guide/pa-files/PAR-24-147.html). For any inquiries, please contact NIH Grants Information at grantsinfo@nih.gov.